Sosei Looks To Add Value Through Pipeline Progress
Executive Summary
Japan-based Sosei is building up its portfolio of in-house assets on top of technology and molecule licensing deals as it looks to create value over the next few years following the acquisition of Heptares, say executives.
You may also be interested in...
Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion
Japan-based Sosei's recent equity offering made its shareholder base more international and will help finance the evolution of the group's proprietary pipeline.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.